The week in pharma: action, reaction and insight – week to March 24, 2023

27 March 2023

By Barbara Obstoj-Cardwell. Editor

Clinical trial news last week included Japanese pharma giant Takeda presenting strong Phase IIb data at the American Academy of Dermatology meeting on its psoriasis asset TAK-279, which it licensed from Nimbus Therapeutics for a massive $4 billion upfront. Also, the USA’s 89bio was boosted last Wednesday with the release of encouraging results for its non-alcoholic steatohepatitis (NASH) candidate pegozafermin. And Sanofi last Thursday released stunning results for its blockbuster drug Dupixent in the treatment of chronic obstructive pulmonary disease (COPD). Elsewhere, in a move to broaden its pipeline, Germany’s BioNTech has licensed an oncology candidate, ONC-392, from USA-based OncoC4, paying an upfront $200 million. Also, last week saw US biotech Incyte gain Food and Drug Administration (FDA) approval of Zynyz for the treatment of locally advanced Merkel cell carcinoma.

AAD 2023 – Takeda outdoes Bristol’s Sotyktu

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK